[144] Taboola.com Ltd. SEC Filing

Rhea-AI Filing Summary

Telomir Pharmaceuticals (NASDAQ: TELO) filed an 8-K disclosing that on 18 July 2025 it sold 1,100,000 common shares through its at-the-market facility at an average price of $2.6045, a premium to the prior day’s close. The block trades were placed with institutional investors and executed by Rodman & Renshaw on the StockBlock platform. Gross proceeds totalled ≈$2.9 million before fees; no warrants or other equity sweeteners were issued.

The transaction immediately increases cash while modestly diluting existing shareholders via the new share issuance. Because the raise was completed at a premium and without warrant overhang, the near-term balance-sheet impact is positive, though future EPS will be spread over a larger share count.

Positive

• $2.9 million gross proceeds improve short-term liquidity.
• Shares were sold at a premium to prior close, indicating investor demand.
• Financing involved no warrants, avoiding future overhang.

Negative

• Issuance of 1.1 million new shares dilutes existing shareholders.

Insights

Financial Analyst

TL;DR: Small ATM raise nets $2.9 m at premium; cash up, dilution modest, overall neutral-positive for liquidity.

The company tapped its at-the-market program for 1.1 m shares, obtaining a premium price without warrants—a sign of institutional appetite and reduced financing risk. While the cash infusion is relatively minor, biopharma firms often need steady capital; this raise buys time without onerous terms. Share count rises, so per-share metrics will edge down, but the absence of discounts or warrant coverage limits pressure on the stock. Given the size, I view the event as liquidity-enhancing yet not transformational.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	19724	70022.17	321404866	07/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2025	Restricted Stock	Issuer			19724	05/01/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	07/15/2025	18005	65363.55
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	07/11/2025	18006	65916.36
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	07/07/2025	14803	54327.01
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	06/30/2025	14802	54323.34
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	06/23/2025	19370	69927.64
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	06/18/2025	15000	54765.00
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	06/11/2025	10000	36012.00
LYNDA CLARIZIO 16 Madison Square West 7th Floor New York NY 10010	Common	06/10/2025	7000	24817.10

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares did Telomir Pharmaceuticals sell in the July 2025 offering?

The company sold 1,100,000 common shares through its at-the-market facility.

What price did TELO obtain for the new shares?

Shares were placed at an average price of $2.6045, a premium to the previous trading day’s close.

How much capital did Telomir Pharmaceuticals raise?

Gross proceeds were approximately $2.9 million before fees and expenses.

Were any warrants issued with this financing?

No, the offering did not include warrants; only common shares were sold.

Who facilitated the block trades for TELO’s offering?

Trades were executed by Rodman & Renshaw via the StockBlock platform.